Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 6/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 4/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalorphine SCHEMBL6908593 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL17771837 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL12030798 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL14124636 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL16015635 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL12230555 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL12091243 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL19199030 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL1883694 | 0.99 | OPRM1 (0.98) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL149571 | 0.99 | OPRM1 (0.98) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13802 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617816-B2 | Composition and method for in vivo assay of opioid receptors | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2026-05-05 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-4358962-B1 | TREATMENT FOR AUTOIMMUNE DISEASES COMPRISING NALTREXONE OR A METABOLITE OR ANALOG THEREOF, A CANNABINOID AND A 5-HT RECEPTOR AGONIST | LDN PHARMA LTD (GB) | 2026-02-04 | — | — | EP | claimed |
| EP-4100010-B1 | NITROXIDE COMPOUNDS FOR USE IN THE TREATMENT OF OPIOID-INDUCED RESPIRATORY DEPRESSION (OIRD) | UNIV CASE WESTERN RESERVE (US) | 2026-01-07 | — | — | EP | claimed |
| US-12472202-B2 | Compositions and their use in the treatment of endometriosis and pain | RR Medsciences PTY, LTD (AU) | 2025-11-18 | — | — | US | claimed |
| US-20250333731-A1 | TRANSCRIPTIONALLY RECORDING CELL COMPOSITION AND METHOD FOR NON-INVASIVE ASSESSMENT OF GUT FUNCTION | ETH ZURICH (CH) | 2025-10-30 | — | — | US | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-12377065-B2 | Compositions for treatment of substance use disorder | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2025-08-05 | — | — | US | claimed |
| US-4434168-A | Narcotic antagonists in the therapy of shock | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1984-02-28 | — | — | US | claimed |
| EP-0078434-A1 | Pharmaceutical and dietary compositions | EFAMOL LIMITED (GB) | 1983-05-11 | — | — | EP | claimed |
| EP-0077393-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | The University of Kentucky Research Foundation (US) | 1983-04-27 | — | — | EP | claimed |
| EP-0071357-A1 | Pharmaceutical and dietary composition when used for enhancement of 1-series PG production | EFAMOL LIMITED (GB) | 1983-02-09 | — | — | EP | claimed |
| WO-1982003768-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | UNIV KENTUCKY (US) | 1982-11-11 | — | — | WO | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| EP-0037175-A1 | Pharmaceutical compositions | EFAMOL LIMITED (GB) | 1981-10-07 | — | — | EP | claimed |
| EP-0035856-A2 | Pharmaceutical and dietary compositions | EFAMOL LIMITED (GB) | 1981-09-16 | — | — | EP | claimed |
| US-4267182-A | Narcotic antagonists in the therapy of shock | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1981-05-12 | — | — | US | claimed |
| EP-0019423-A1 | Pharmaceutical and dietary composition comprising gamma-linolenic acids | EFAMOL LIMITED (GB) | 1980-11-26 | — | — | EP | claimed |